FDA Guide Cuts Animal Testing for New Drugs
Published Date: 3/19/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers use new, smarter testing methods that can reduce animal testing and better predict human safety. This affects drug developers who want to submit safer, more reliable data for approval. Comments are open until May 18, 2026, so get involved early to shape the final rules and possibly save time and money in drug development.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Encourages Use of NAMs in Submissions
If you develop drugs, FDA published a draft guidance that gives a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The guidance covers using nonclinical NAM data to support regulatory submissions (for example, investigational new drug applications and biologics license applications), encourages early engagement with drug review divisions, and is open for comment through May 18, 2026.
NAMs Apply to OTC Topical Monograph Orders
If you make nonprescription topical (OTC) drugs, the draft guidance says NAMs can be used to support nonclinical data for OTC monograph orders issued under section 505G of the FD&C Act. FDA issued this draft guidance in part to satisfy the requirement under section 505G(r)(2)(B), and it is open for comment through May 18, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-05389, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; CHIPS Workforce Solution Participant Data Collection
The Department of Commerce is asking for public feedback on a new data collection for the CHIPS Workforce Solution program, which helps track how semiconductor companies use workforce funding. This affects companies receiving CHIPS funds and aims to make reporting easier while ensuring the government gets useful info. Comments are open until May 18, 2026, so don’t miss your chance to weigh in!
Next: 2026-05391, 60-Day Notice of Proposed Information Collection: Risk Analysis and Management (RAM) OMB Control Number 1405-0204
The Department of State wants to keep collecting info from contractors and grantees to help manage risks better. They’re asking for public feedback by May 18, 2026, before renewing this paperwork, which takes about 1.5 hours per response. This update won’t cost you money but helps keep things safe and smooth for everyone involved.